TrialAnnals of clinical and translational neurology2022

A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.

Jonathan S Katz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.